Expression of Inositol, 1,4,5-trisphosphate Receptor in the Nucleus of Human Benign and Malignant Squamous Cells and Its Significance
肌醇、1,4,5-三磷酸受体在人良恶性鳞状细胞核中的表达及其意义
基本信息
- 批准号:07671858
- 负责人:
- 金额:$ 1.34万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1995
- 资助国家:日本
- 起止时间:1995 至 1996
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Inositol 1,4,5-trisphosphate (IP_3) is one of the important messengers of the intracellular signal transduction, and controls the cytoplasmic flow of calcium ion in conjunction with its receptor (IP_3-R). The Ip_3-R protein and its coding gene had been revealed by Mikoshiba et al., and monoclonal antibodies reactive with mouse IP_3-R protein have been produced as well. Using cross-reactivity of these monoclonal antibodies (10A6,4C11,18A10) with the human counterpart we have shown the distribution of IP_3-R in human tissues and cells, especially in normal skin including benign squamous epithel, squamous cell carcinoma-tissues and cultured cell lines of squamous cell carcinoma. In the present researchproject we examined peculiar reactivity of 10A6 monoclonal antibody with an antigen in the nucleus. Presence of the antigen was most clearly shown in the nuclei of cultured squamous carcinoma cells. Observation by confocal laser scanning microscopy revealed its fine granular distribution in the nucleus but not in the nucleolus. The amount of the antigen as assessed by fluorescence intensity of immunostaining differed among cell lines, but there were no correlation with the stage of differentiation in squamous cell lineage or to the tissues where carcinoma arose. Attempt to reveal ultrastructural localization did not succeed because of the weaknees of the antigenicity againt various fixatives. Since funcitonal analysis indicates the presence of IP_3-R only in the nuclear membrane but not in the nucleus, 10A6 monoclonal antibody might react with crossreacting antigen other than IP_3-R protein itself. Further investigation to reveal nature of the antigen in the nucleus of human cells is now in progress.
肌醇1,4,5-三磷酸(IP_3)是细胞内信号转导的重要信使之一,与其受体(IP_3-R)共同调控细胞内钙离子的流动。Mikoshiba等人已经发现了Ip_3-R蛋白及其编码基因,并制备了与小鼠IP_3-R蛋白反应的单抗。利用这些单抗(10A6、4C11、18A10)与人的交叉反应,我们显示了IP_3-R在人体组织和细胞中的分布,特别是在正常皮肤,包括良性鳞状上皮、鳞状细胞癌组织和鳞癌培养细胞系中。在本研究项目中,我们检测了10A6单抗与细胞核内抗原的特异性反应性。在培养的鳞状癌细胞的细胞核中,该抗原的存在最为明显。激光共聚焦扫描显微镜观察发现,其细小颗粒分布在细胞核内,但不在核仁内。免疫组织化学染色的荧光强度测定的抗原含量在不同的细胞系中不同,但与鳞状细胞系的分化阶段或发生癌的组织无关。试图揭示超微结构的定位没有成功,因为对各种固定剂的抗原性很弱。由于功能分析表明IP_3-R仅存在于核膜上,而不存在于细胞核内,因此,10A6单抗可能与交叉反应的抗原反应,而不是与IP_3-R蛋白本身发生反应。目前正在进行进一步的研究,以揭示人类细胞核中这种抗原的性质。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hiromi Shiba: "The effects of calcium ionophore A23187 and TPA on the expression of IP3-receptor in human B cell lines" Acta Histochemica et cytochemica. 27(4). 387- (1994)
Hiromi Shiba:“钙离子载体 A23187 和 TPA 对人类 B 细胞系中 IP3 受体表达的影响”《组织化学与细胞化学学报》。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hiromi Shiba: "The effects of calcium ionophore A23187 and TPA on the expression of IP3-receptor in human B cell lines." Acta Histochemica et cytochemica. 27 (4). 387 (1994)
Hiromi Shiba:“钙离子载体 A23187 和 TPA 对人类 B 细胞系中 IP3 受体表达的影响。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Taiji Katoh: "Immunoreactivity of an anti-mouse inositol 1, 4, 5-trisphosphate receptor monoclonal anitbody with the nuclear antigen of the human cells." Acta Histochemica et cytochemica.27(4). 423- (1994)
Taiji Katoh:“抗小鼠肌醇 1,4,5-三磷酸受体单克隆抗体与人类细胞核抗原的免疫反应性。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Taiji Katoh: "Immunoreactivity of an antimouse inositol 1,4,5-trisphosphate receptor monoclonal antibody with the nuclear antigen of the human cells." Acta Histochemica et cytochemica. 27 (4). 423 (1994)
Taiji Katoh:“抗小鼠肌醇 1,4,5-三磷酸受体单克隆抗体与人类细胞核抗原的免疫反应性。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HARADA Takayuki其他文献
HARADA Takayuki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HARADA Takayuki', 18)}}的其他基金
Layered metallic material/semiconductor heterostructures for harsh-environment electronics
用于恶劣环境电子产品的层状金属材料/半导体异质结构
- 批准号:
20H02611 - 财政年份:2020
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Establishment of animal models of neurodegenerative diseases and development of therapeutic strategies utilizing optogenetics
神经退行性疾病动物模型的建立及光遗传学治疗策略的开发
- 批准号:
18K19625 - 财政年份:2018
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Generation of a marmoset model of normal tension glaucoma and investigation into neuroprotection and neuroregeneration for glaucoma therapy
正常眼压青光眼狨猴模型的建立及青光眼治疗的神经保护和神经再生研究
- 批准号:
15H04999 - 财政年份:2015
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Functional analyses of the role of oncomodulin in axon regeneration
癌调节蛋白在轴突再生中作用的功能分析
- 批准号:
26640048 - 财政年份:2014
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
The development of community-based treatment program for substance use disorder
药物滥用障碍社区治疗计划的制定
- 批准号:
26380947 - 财政年份:2014
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of a coping skills training program for craving control of methamphetamine users
制定应对技巧培训计划以控制甲基苯丙胺使用者的渴望
- 批准号:
22530754 - 财政年份:2010
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of the pathogenesis of normal tension glaucoma and the development of its treatment by neuroprotection and axon regeneration
阐明正常眼压性青光眼的发病机制以及神经保护和轴突再生治疗的进展
- 批准号:
19390447 - 财政年份:2007
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
In Situ Immunocytological and Molecular Pathological Analysis of the Lesions in the Target Organs of Chronic GvH Disease
慢性GvH病靶器官病变的原位免疫细胞学和分子病理学分析
- 批准号:
06670225 - 财政年份:1994
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Analysis of the antioxidant function of xCT in lymphatic endothelial cells and its significance in oral squamous cell carcinoma.
淋巴管内皮细胞xCT抗氧化功能分析及其在口腔鳞癌中的意义
- 批准号:
23K16139 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Search for therapeutic target molecules based on temporal hierarchical analysis of Oral squamous cell carcinoma and functional RNA molecules
基于口腔鳞状细胞癌和功能RNA分子的时间层次分析寻找治疗靶分子
- 批准号:
23K16142 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of miR-27a* for the Treatment of Head and Neck Squamous Cell Carcinoma
开发 miR-27a* 用于治疗头颈鳞状细胞癌
- 批准号:
10752726 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:
Investigating a new vulnerability in oral squamous cell carcinoma
研究口腔鳞状细胞癌的新脆弱性
- 批准号:
10714352 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:
"Role of Amplified Protein Kinases in Head and Neck Squamous Cell Carcinoma Progression and Therapy Resistance."
“扩增的蛋白激酶在头颈鳞状细胞癌进展和治疗耐药中的作用。”
- 批准号:
10725901 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:
HMGB1 in EB-Associated Squamous Cell Carcinoma
EB 相关鳞状细胞癌中的 HMGB1
- 批准号:
10676346 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:
Functional heterogeneity of cancer-associated fibroblasts in head and neck squamous cell carcinoma and development of therapeutic strategies
头颈鳞状细胞癌中癌症相关成纤维细胞的功能异质性及治疗策略的开发
- 批准号:
23K08956 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of treatment to lymph node metastasis by Epitranscriptome regulation in Esophageal squamous cell carcinoma
表观转录组调控食管鳞癌淋巴结转移治疗进展
- 批准号:
23K15512 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanisms of Pip4k2c and Pip5k1b dependencies in Ras driven squamous cell carcinoma
Ras 驱动的鳞状细胞癌中 Pip4k2c 和 Pip5k1b 依赖性的机制
- 批准号:
10667117 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck
个体化疫苗免疫疗法联合抗 PD 1 抗体治疗复发性或转移性头颈部鳞状细胞癌
- 批准号:
10658577 - 财政年份:2023
- 资助金额:
$ 1.34万 - 项目类别:














{{item.name}}会员




